Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/50

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/203397ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF
WO 14.10.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2020/084097 Applicant TSB THERAPEUTICS (BEIJING) CO. LTD. Inventor ZHANG, Zheng
Provided herein are novel anti-SARS-COV-2 antibodies or antigen binding fragments thereof, pharmaceutical composition and kits comprising the same, and the uses thereof.
2.WO/2021/205408IGY IMMUNOGLOBULINS TARGETING CORONAVIRUS, METHODS OF PREPARING SAME, AND METHODS OF USING SAME
WO 14.10.2021
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/IB2021/052977 Applicant IGY IMMUNE TECHNOLOGIES AND LIFE SCIENCES INC. Inventor NGUYEN, Huan Huu
The present disclosure provides a method of preparing compositions or vaccines for immunizing or vaccinating egg-laying fowl such as hens against coronavirus. The eggs can be collected and the coronavirus-specific IgY antibodies can be extracted and purified. The coronavirus-specific IgY immunoglobulin composition can be used to treat individuals exposed to, susceptible to, or infected with coronavirus.
3.WO/2021/206581GENETIC CONSTRUCT-BASED VACCINE AGAINST CORONAVIRUS INFECTION
WO 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/RU2020/000257 Applicant DUKHOVLINOV, Ilya Vladimirovich Inventor DUKHOVLINOV, Ilya Vladimirovich
The invention relates to molecular biology, biotechnology, medicine and can be used to prevent and treat corona virus infection, mainly caused by 2019-nCoV. A vaccine is proposed based on a genetic construct encoding a fusion protein, including fragments of M, S, N, E new coronavirus proteins. The speed and simplicity of preparation (from 2-3 hours to 4-5 days), safety are the advantages of the developed vaccine, due to the nature of the molecule- of the active substance, as well as to the lack of an ACE2 binding site in the fusion protein synthesized from the genetic construct, and the lack of its homology with proteins of the organism, induction of the immune response profile, to a large extent represented by the cytotoxic immune response, in addition to the humoral one. The vaccine can be administered as standard or by electroporation.
4.WO/2021/200717IMPROVED METHOD OF VIRUS DETECTION
WO 07.10.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/JP2021/013045 Applicant TOYOBO CO., LTD. Inventor TERAUCHI Kenta
The purpose of the present invention is to provide a method and a kit whereby the presence of an enveloped RNA virus (for example, a coronavirus) in a sample can be detected easily in a short amount of time. Provided is a method for testing an enveloped RNA virus in a sample, said method being characterized by including the following steps (1) to (3): (1) a step in which a sample that has not been subjected to nucleic acid separation/purification treatment is mixed with a reagent containing an alkaline solution; (2) a step in which a one-step RT-PCR reaction solution containing (i) a reverse transcriptase and a DNA polymerase or (ii) a DNA polymerase having reverse transcription activity is added to the liquid mixture described above at least one minute after preparing the liquid mixture; and (3) a step in which the reaction container is sealed and a one-step RT-PCR reaction is then performed.
5.WO/2021/198963VECTORS FOR PRODUCING VIRUS-LIKE PARTICLES AND USES THEREOF
WO 07.10.2021
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/IB2021/052710 Applicant MEDIPHAGE BIOCEUTICALS, INC. Inventor SLAVCEV, Roderick
The present disclosure provides expression vectors and bacterial sequence-free vectors, such as ministring DNA (msDNA), for producing virus-like particles (VLPs) as well as compositions and methods thereof. In some aspects, the methods include treating viral infections in subjects with the vectors, compositions, and VLPs.
6.WO/2021/198769VACCINE COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS
WO 07.10.2021
Int.Class A61K 39/385
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
385Haptens or antigens, bound to carriers
Appl.No PCT/IB2021/000190 Applicant VARIATION BIOTECHNOLOGIES INC. Inventor ANDERSON, David, Evander
The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
7.WO/2021/200800VACCINE FOR PREVENTING OR TREATING CORONAVIRUS INFECTION OR SYMPTOMS ASSOCIATED WITH CORONAVIRUS INFECTION
WO 07.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/JP2021/013237 Applicant OSAKA UNIVERSITY Inventor NAKAGAMI, Hironori
The present invention provides a vaccine to be used for preventing or treating coronavirus infection and symptoms associated with coronavirus infection.
8.WO/2021/193862IMPROVED METHOD OF VIRUS DETECTION
WO 30.09.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/JP2021/012699 Applicant TOYOBO CO., LTD. Inventor TERAUCHI Kenta
The purpose of the present invention is to provide a method and a kit by which the presence of an enveloped RNA virus (for example, a corona virus) in a sample can be easily detected within a short period of time. A method for testing an enveloped RNA virus in a sample, said method being characterized by comprising steps (1) to (3): (1) a step for mixing a sample, which has not been subjected to a nucleic acid separation and purification treatment, with a reagent containing a polar solvent; (2) a step for adding, to the liquid mixture obtained above, a one-step RT-PCR reaction solution containing (i) a reverse transcriptase and a DNA polymerase, or (ii) a DNA polymerase having reverse transcription activity; and (3) a step for sealing the reaction container and then performing a one-step RT-PCR reaction.
9.113444155MERS-CoV膜蛋白受体结合域二聚体及其编码基因和应用
CN 28.09.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202010418710.1 Applicant 清华大学 Inventor 张林琦
本发明公开了MERS‑CoV膜蛋白受体结合域二聚体及其编码基因和应用。本发明首保护MERS‑CoV RBD的二聚体;MERS‑CoV RBD为序列表的序列3所示的蛋白质或者序列表的序列7所示的蛋白质。本发明确定了中东呼吸综合征冠状病毒膜蛋白受体结合域二聚体(MERS‑CoV RBD dimer)的结构和免疫原性。进一步的,本发明发现,MERS‑CoV RBD dimer的免疫原性比MERS‑CoV RBD monomer更好,更能在动物体内诱导产生较强的中和抗体反应。本发现对研发治疗和预防中东呼吸综合征的疫苗等具有重要的理论指导价值和广泛的应用前景。
10.113444156新型冠状病毒肺炎重组人5型腺病毒疫苗
CN 28.09.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 202110628544.2 Applicant 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) Inventor 步志高
本发明提供一种包含改造的SARS‑CoV‑2的刺突蛋白的疫苗组合物,该疫苗组合物将复制缺陷型人5型腺病毒rAd病毒株与新型改造的SARS‑CoV‑2的刺突蛋白(S6P)或其免疫原性衍生物结合构建重组复制缺陷型人5型腺病毒,用于预防新型冠状病毒的感染,尤其是针对哺乳动物的新型冠状病毒的感染。